

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John B. Harley and Judith A. James

Serial No.: Divisional of 10/012,756 Art Unit: Not Yet Assigned

Filed: June 27, 2003 Examiner: Not Yet Assigned

For: *DIAGNOSTICS AND THERAPY OF EPSTEIN-BARR VIRUS IN AUTOIMMUNE DISORDERS*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including twenty-three (23) pages of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 10/012,756, filed October 24, 2001, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S.S.N.: Divisional of 10/012,756  
 Filed: June 27, 2003  
 INFORMATION DISCLOSURE STATEMENT

### U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,554,101	11-19-1985	Hopp	514/17
4,654,419	03-31-1987	Vaughan	530/326
4,707,358	11-17-1987	Kieff	424/89
4,784,942	11-15-1988	Harley	435/7
4,865,970	09-12-1989	Brot, et al.	435/7
5,312,752	05-17-1994	Woltz, et al.	435/240.27
5,354,691	10-11-1994	Van Eden, et al.	436/506
5,637,454	06-10-1987	Harley	435/5
5,679,774	10-21-1997	Wolf	530/350
5,723,283	03-03-1998	Classen	435/4
5,726,286	03-10-1998	Alderson	530/300
5,874,531	02-23-1999	Strominger, et al.	530/326
5,965,353	10-12-1999	Middeldorp	435/5

### Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 113 431 B1	07-18-1984	Yeshiva University	EP
0 313 156 A1	04-26-1989	Akzo N.V.	EP
WO 86/01210	02-27-1986	Scripps Clinic Res.	PCT
WO 88/09932	06-03-1988	Amrad Corporation Ltd.	PCT
WO 91/11718	08-08-1991	Board of Regents of the University of Oklahoma	PCT
WO 91/17171	11-14-1991	Oklahoma Medical Research Foundation	PCT
WO 91/18920	12-12-1991	Neosystem	PCT
WO 93/21223	10-28-1993	Board of Regents of the University of Oklahoma	PCT
WO 94/02445	02-03-1994	Yeda Research and Development Co. Ltd. at Weizmann Institute of Science	PCT
WO 94/02509	02-03-1994	Rijksuniversiteit Leiden	PCT
WO 94/06912	03-31-1994	Middeldorp	PCT
WO 94/21669	09-29-1994	Medclone, Inc.	PCT
WO 96/37225	11-28-1996	Oklahoma Medical Research Foundation	PCT

## Publications

ALEXANDER, et al., "Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, and Experimental Model," *Arth. And Rheum.* 35:176-189 (1992).

ARBUCKLE, et al., "Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus," *Scand. J. Immunol.* 50(5):447-55 (1999).

BANERJEE, et al., "Complete Nucleotide Sequence of the mRNA Coding for the N Protein of Vesicular Stomatitis Virus (New Jersey Serotype)," *Virology* 137:432-438 (1984).

BARAKET, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," *Clin. Exp. Immunol.* 89:38-45 (1992).

BARAKET, et al., "Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera," *Clin. Exp. Immunol.* 86:71-78 (1991).

BARAKET, et al., "Recognition of Synthetic Peptides of Sm-D Autoantigen by Lupus Sera," *Clin. Exp. Immunol.* 81:256-262 (1990).

BEN-CHETRIT, et al., "Isolation and Characterization of a cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," *J. Clin. Inv.* 83:1284-1292 (1989).

BLANK, et al., "Induction of Experimental Anti-phospholipid Syndrome Associated with SLE Following Immunization with Human Monoclonal Pathogenic Anti-DNA Idiotype," *J. Autoimmunity* 5:495-509 (1992).

BLANK, et al., "Induction of SLE-Like Disease in Naive Mice with a Monoclonal anti-DNA Antibody Derived from a Patient with Polymyositis carrying the 16/6 id," *J. Autoimmunity* 1:683-591 (1988).

BLANK, et al., "Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody SA-1 (16/6 Id+) and for Mouse Tuberculosis Antibody TB/68 (16/6 id+) *Clin. Immunol. Immunopathol.* 60:471-483 (1991).

BLANK, et al., "Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti-DNA Idiotype in Naive Mice," *J. Rheumatol.* 17:311-317 (1990).

INFORMATION DISCLOSURE STATEMENT

BLANK, et al., "The Effect of the Immunomodulator Agent AS101 on Interleukin-2 Production in Systemic Lupus Erythematosus (SLE) Induced in Mice by Pathogenic Anti-DNA Antibody," *Clin. Exp. Immunol.* 79:443-447 (1990).

BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," *Arch. Neurol.* 42:1798-1804 (1992).

BRAY, et al., "Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis," *Arch. Neurology* 40:406-408 (1983).

BUYON, "Neonatal Lupus Syndrome," *Curr. Opin. In Rheum.* 6:523-529 (1994).

CHAMBERS, et al., "Genomic Structure and Amino Acid Sequence domains of the Human La Autoantigen," *J. Biol. Chem.* 263:18043-18051 (1988).

CHAMBERS, et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," *Proc. Natl. Acad. Sci. USA* 82:2115-2119 (1985).

CHAN, et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," *Nucl. Acids Res.* 17:2233-2244 (1989).

COHEN, "The Self, the World and Autoimmunity - Autoimmunity - In Which the Immune System Recognizes and Attacks the Self's Own Tissues - Is Not as Simple as it Seemed. Self-recognition Appears to be at the Heart of Health as Well as of Certain Diseases," *Scientific American* 258:52-60 (1988).

CRAFT, et al., "Murine and Drosophila B Proteins of SM snRNPs," *Mol. Biol. Rep.* 15:159 (1991).

CRONE, et al., "Viral Transcription is Necessary and Sufficient for Vesicular Stomatitis Virus to Inhibit Maturation of Small Nuclear Ribonucleoproteins," *Journal of Virology* 63(10):4172-4180 (1989).

CUNNINGHAM, et al., "Human Monoclonal Antibodies Reactive with Antigens of the Group A Streptococcus and Human Heart," *Journal of Immunology* 141(8):2760-2766 (1988).

DALLDORF, et al., "The Lymphomas of Brazilian Children," *J. Am. Med. Assn.* 208:1365-8 (1969).

DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," *J. Pathol.* 163:351-360 (1991).

INFORMATION DISCLOSURE STATEMENT

DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," *Am J. Med.* 92:453-454 (1992).

DEPOLO, et al., "Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering Particles," *J. of Virology* 61:454-464 (1987).

DEUTSCHER, et al., "Molecular Analysis of the 60-kDa Human Ro Ribonucleoprotein," *Proc. Natl. Acad. Sci. USA* 85:9479-83 (1988).

DICKEY, "Human Autoantibody Producing Grafts in SCID Mice," presented to the Oklahoma Lups Association, Inc., Sept. 1, 1989.

DYRBERG & OLDSSTONE, "Peptides as Probes to Study Molecular Mimicry and Virus-Induced Autoimmunity," *Current Topics in Microbiology and Immunology* 130:25-37 (1986).

ELKON, et al., "Epitope Mapping of Recombinant HeLa SmB and B' Peptides Obtained by the Polymerase Chain Reaction," *J. Immun.* 145:636-643 (1990).

ESQUIVEL, et al., "Induction of Autoimmunity in Good and Poor Responder Mice with Mouse Thyroglobulin and Lipopolysaccharide," *J. Exp. Med.* 145:1250-1263 (1977).

EVANS & NIEDERMAN, "Epstein-Barr virus" in Viral Infections in Humans, 3rd ed. Evans, A.S. ed. pp 265-292 (Plenum, New York City 1989).

EVANS & ROTHFIELD, "E.B. Virus and Other Viral Antibodies in Systemic Lupus Erythematosus," *Lancet* 1:1127-1128 (1973).

EVANS, "E.B. Virus Antibody in Systemic Lupus Erythematosus" *Lancet* 1:1023-4 (1971).

EVANS, et al., "Raised Antibody Titres to E.B. Virus in Systemic Lupus Erythematosus," *Lancet* 1:167-168 (1971).

FERRIS & DONALDSON, *Veterinary Microbiology* 18(3-4):243-258 (1988).

FINERTY, et al., "Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," *Vaccine* 12:1180-1184 (1994).

FINERTY, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector," *J. Gen. Virol.* 73:449-453 (1992).

FOX, "Sjogren's Syndrome," *Current Opin. Rheum.* 7:409-416 (1995).

FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," *J. Immunol.* 137:3162-3168 (1986).

FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," *J. Rheumatol.* 19:18-24 (1992).

FRICKE, et al., "Induction of Experimental Systemic Lupus Erythematosus in Mice by Immunization with a Monoclonal Anti-La Autoantibody," *Intern. Immunol.* 2:225-230 (1990).

FRITZ, et al., "Small Nuclear U-Ribonucleoproteins in *Xenopus Laevis* Development," *J. Mol. Biol.* 178:273-285 (1984).

GAITHER, et al., "Implications of Anti-Ro/Sjogren's Syndrome a Antigen Autoantibody in Normal Sera for Autoimmunity," *J. Clin. Invest.* 79:841-846 (1987).

GAITHER, et al., "Affinity Purification and Immunoassay of Anti-Ro/SSA" *Peptides Biol. Fluids* 33:413-416 (1985).

GALLIONE, et al., "Nucleotide Sequences of the mRNA's Encoding the Vesicular Stomatitis Virus N and NS Proteins," *Virology* 39:529-535 (1981).

GAUTAM, et al., "A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis," *J. Immunol.* 161:60-64 (1998).

GERGELY, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus," *Lancet* 1:325-326 (1973).

GEYSEN, et al., "Strategies for Epitope Analysis Using Peptide Synthesis," *J. of Immunol. Meth.* 102:259-274 (1987).

GEYSEN, et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984).

GRABOWSKI, et al., "Drosophila AP3, a Presumptive DNA Repair Protein, is Homologous to Human Ribosomal Associated Protein PO," *Nucleic Acids Research* 19(15):4297 (1991).

GU, et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," *Dev. Biol. Stand.* 84:171-177 (1995).

INFORMATION DISCLOSURE STATEMENT

GULDNER, et al., "Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera." *The Journal of Immunology* 141(2):469-475 (1988).

GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," *Cancer Res.* 56:969-972 (1996).

HAAHR, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease," *Ann. N. Y. Acad. Sci.* 724:148-156 (1996).

HAHN, "Suppression of Autoimmune Diseases with Anti-idiotypic Antibodies: Murine Lupus Nephritis as a Model" Springer Seminars in Immunopathology, 7(1):25-34 (1984).

HARDGRAVE, et al., "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," *Arthritis and Rheumatism* 36(7):962-970 (1993).

HARLEY & GAITHER, "Autoantibodies" *Rheum. Dis. Clin. N. Amer.* 14:43-56 (1992).

HARLEY & JAMES, "Review Articles: Autoepitopes in Lupus," *J. Lab. Clin. Med.* 126(6):509-516 (1995).

HARLEY, et al., "Gene Interaction at HLA-DQ Enhances Autoantibody Production in Primary Sjogren's Syndrome," *Science* 232:1145-1147 (1986).

HARLEY, et al., "Anti-Ro (SS-A) and Anti-La (SS-B) in Patients with Sjogren's Syndrome," *Arthritis Rheum.* 29:196-206 (1986).

HARLEY, et al., "Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers," *Arthritis Rheum.* 42(8):1782-3 (1999).

HERBERT, et al., Dictionary of Immunology 3<sup>rd</sup> Ed. Blackwell Scientific Publications Oxford UK page 14 (1985).

HESLOP, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes," *Nature Med.* 2:551-555 (1996).

HINTERBERGER, "Isolation of Small Nuclear Ribonucleoproteins Containing U1, U2, U4, U5, and U6 RNAs," *J. Biol. Chem.* 258:2604-2613 (1983).

HOLLINGER, et al., "Seroepidemiologic Studies in Systemic Lupus Erythematosus," *Bact. Proc.* 131:174 (1970).

INFORMATION DISCLOSURE STATEMENT

HORSFALL, et al., "Ro and La Antigens and Maternal Anti-La Idiotype on the Surface of Myocardial Fibers in Congenital heart Block," *J. of Autoimmun.* 4:165-176 (1991).

HUANG, et al., "Human Anti-Ro Autoantibodies Bind Peptides Accessible to the Surface of the Native Ro Autoantigen," *Scand. J. Immunol.* 41:220-228 (1995).

HUANG, et al., "Immunization with Vesicular Stomatitis Virus Nucleocapsid Protein induces Autoantibodies to the 60 kD Ro Ribonucleoprotein Particle," *J. Invest. Med.* 43:151-158 (1995).

HURD, et al., "Formation of Leukocyte Inclusions in Normal Polymorphonuclear Cells Incubated with Synovial Fluid," *Arthritis Rheum.* 13:724-733 (1970).

INOUE, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis," *J. Infect. Dis.* 164:22-28 (1991).

ISHII, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection," *Immunol. Cell Biol.* 73:463-468 (1995).

JAMES & HARLEY, "Human Lupus Anti-Spliceosome A Protein Autoantibodies Bind Contiguous Surface Structures and Segregate into Two Sequential Epitope Binding Patterns," *J. Immunol.* 4018-4026 (1994).

JAMES & HARLEY, "A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice," *J. Immunol.* 160(1):502-8 (1998).

JAMES & HARLEY, "Linear Epitope Mapping of an Sm B/B' Polypeptide," *J. Immunol.* 148:2074-2079 (1992).

JAMES & HARLEY, "Peptide Autoantigenicity of the Small Nuclear Ribonucleoprotein C," *Clin. And Exp. Rheum.* 13:299-305 (1995).

JAMES & HARLEY, "Sequential Fine Specificity of the Small Nuclear Ribonuclear Protein C," *Clinical Res.* 41(2):PA393 (1993).

JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," *J. Exp. Med.* 181:453-461 (1995).

JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," *J. Clin. Invest.* 100:3019-26 (1997).

INFORMATION DISCLOSURE STATEMENT

JAMES, et al., "Basic Amino Acids Predominate in the Sequential Autoantigenic Determinants of the Small Nuclear 70K Ribonucleoprotein," *Scand. J. Immunol.* 39:557-566 (1994).

JAMES, et al., "Inbred Mice Strains Differ in Their Capacity to Develop Spliceosomal Autoimmunity After Peptide Immunization," *Arthritis Rheum.* 38:S226 (1995).

JAMES, et al., "Lupus Humoral Autoimmunity After Short Peptide Immunization<sup>a</sup>," *Arthritis Rheum.* 39:S216 (1996).

JAMES, et al., "Lupus humoral autoimmunity after short peptide immunization," *Ann. N. Y. Acad. Sci.* 815:124-7 (1997).

JAMES, et al., "Sequential Autoantigenic Determinants of the Small Nuclear Ribonucleoprotein Sm D Shared by Human Lupus Autoantibodies and MRL *lpr/lpr* Antibodies," *Clin. Exp. Immunol.* 98:419-426 (1994).

KALUSH, et al., "Neonatal Lupus Erythematosus with Cadian Involvement in Offspring of Mothers with Experimental Systemic Lupus Erythematosus," *J. of Clin. Immunol.* 14:314-321 (1994).

KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an *in situ* Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," *Clin. Exp. Rheum.* 10:327-332 (1992).

KAUFMAN, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Anklosing spondylitis Pathogenesis," *Arthritis Rheum.* 39:S298 (1996)

KIEFF & LIEBOWITZ, Epstein-Barr virus and its replication. In *Virology*, 2nd ed. Fields et al., eds. pp 1889-1921 (Raven Press, New York 1990).

KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," *Immunol. Lett.* 17:249-252 (1988).

KLIPPEL, et al., "Epstein-Barr Virus Antibody and Lymphocyte Tubuloreticular Structures in Systemic Lupus Erythematosus," *Lancet*, 2:1057-1058 (1973).

KURILLA, et al., "The Leader RNA of Vesicular Stomatitis Virus is Bound by a Cellular Protein Reactive with Anti-La Lupus Antibodies," *Cell* 34:837-845 (1983).

KUZUSHIMA, et al., "Establishment of Anti-Epstein-Barr Virus (EBV) Cellular Immunity by Adoptive Transfer of Virus-Specific Cytotoxic T Lymphocytes from an

INFORMATION DISCLOSURE STATEMENT

HLA-matched Sibling to a Patient with Severe chronic Active EBV Infection," *Clin. Exp. Immunol.* 103:192-198 (1996).

LARSEN, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis," *Neurology* 35:435-438 (1985).

LAZAROVITS, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation," *Clin. Invest. Med.* 17:621-625 (1994).

LEE, et al., "Cardiac Immunoglobulin Deposition in Congenital heart Block Associated with Maternal Anti-Ro Autoantibodies," *Am. J. of Med.* 83:793-796 (1987).

LEE, et al., "The Recognition of Human 60-kDa Ro Ribonucleoprotein Particles by Antibodies Associated with Cutaneous Lupus and Neonatal Lupus," *J. Investigative Dermatology* 107(1):225-228 (1996).

LEFF, "Maverick Herpes Receptor Sparks Search for KS Drug," *Bio World Today* 8(17):1 (1997).

LEHMAN, et al., "Spreading of T-Cell Autoimmunity to Cryptic Determinants of an Autoantigen," *Nature* 356:155-157 (1992).

LERNER & STEITZ, "Antibodies to Small Nuclear RNAs Complexed with Proteins are Produced by Patients with Systemic Lupus Erythematosus," *Proc. Natl. Acad. Sci. USA* 76:5495-5499 (1979).

LERNER, et al., "Are snRNPs Involved in Splicing?" *Nature* 283:220-224 (1980).

LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," *Nature* 375:685-688 (1995).

MADDISON, et al., "Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Antigens in SLE," *Arthritis Rheum.* 20:819-824 (1977).

MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," *Am. J. Med.* 96:97 (1994).

MANFREDI, et al., "Molecular Anatomy of an Autoantigen: T and B Epitopes on the Nicotinic Acetylcholine Receptor in Myasthenia Gravis," *J. Lab. Clin. Med.* 120:13-21 (1992).

MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by *in Situ* Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," *Am. J. Med.* 90:286-294 (1991).

MATTER, et al., "Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies," *Arthritis Rheum.* 25:1278-1283 (1982).

MATTIOLI, et al. "Physical Association of Two Nuclear Antigens and Mutual Occurrence of Their Antibodies: The relationship of the SM and RNA protein (MO) Systems in SLE Sera," *J. Immunol.* 110:1318-1324 (1973).

MCALLISTER, et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential Sm Epitope," *EMBO J.* 8:1177-1181 (1989).

MENDLOVIC, et al., "Induction of an SLE-Like Disease in Mice by a Common Anti-DNA Idiotype," *Proc. Natl. Acad. Sci. USA* 85:2260-2264 (1988).

MENDLOVIC, et al., "The Genetic Regulation of the Induction of Experimental SLE," *Immunology* 69:228-236 (1990).

MENDLOVIC, et al., "The Role of Anti-Idiotypic Antibodies in the Induction of Experimental Systemic Lupus Erythematosus in Mice," *Eur. J. Immunol.* 19:729-732 (1989).

MILLER, et al., "The Role of an Autoantigen, Histidyl-tRNA Synthetase, in the Induction and Maintenance of Autoimmunity," *Proc. Natl. Acad. Sci. USA* 87:9933-9937 (1990).

MIYASHITA, et al., "A Novel Form of Epstein-Barr Virus Latency in Normal B Cells In Vivo," *Cell*, 80:593-601 (1995).

MORGAN, "Epstein-Barr Virus Vaccines," *Vaccine* 10:563-571 (1992).

MORGAN, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," *J. Med. Virol.* 29:74-78 (1989).

MORLAND, et al., "Anti-idiotype and Immunosuppressant Treatment of Murine Lupus," *Clin. Exp. Immunol.* 83(1):126-132 (1991).

MORSHED, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients," *Gastroenterol. Jpn.* 27(6):751-758 (1992).

MOSIER, et al., "Transfer of a functional human immune system to mice with severe combined immunodeficiency," *Nature* 335:256-259 (1988).

MUNVES, et al., "Antibodies to Sm and RNP," *Arthritis Rheum.* 26:848-853 (1983).

NEWELL & STEVENS, "E.B. Virus Antibody in Systemic Lupus Erythematosus," *Lancet* 1:652 (1971).

INFORMATION DISCLOSURE STATEMENT

NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," *Br. J. Rhuem.* 33:317-322 (1994).

NICHOLSON, "A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens," *Proc. Natl. Acad. Sci. USA* 94:9279-9284 (1997).

OHOSONE, et al., "Molecular Cloning of cDNA Encoding Sm Autoantigen: Derivation of a cDNA for a B Polypeptide of the U Series of Small Nuclear Ribonucleoprotein Particles," *Proc. Natl. Acad. Sci. USA* 86:4249-4253 (1989).

PALFI, et al, "Purification of the Major UsnRNPs from Broad Bean Nuclear Extracts and Characterization of their Protein Constituents," *Nucleic Acids Res.* 17:1445-1458 (1989).

PETERSEN, et al, "Altered Immune Response to Glycine-Rich Sequences of Epstein-Barr Nuclear Antigen-1 in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," *Arthritis Rheum.* 33:993-1000 (1990).

PETTERSSON, et al., "The Structure of Mammalian Small Nuclear Ribonuceoproteins," *J. Biol. Chem.* 259:5907-5914 (1984).

PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," *Ophthalmology* 97:976-984 (1990).

PFLUGFELDER, et al., "Epstien-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," *Am. J. Pathol.* 143:49-64 (1993).

PHILLIPS & CHRISTIAN, "Myxovirus Antibody Increases in Human Connective Tissue Disease," *Science* 168:982-4 (1970).

PHILLIPS, et al., "Viruses and Systemic Lupus Erythematosus," *Lancet* 1:1449 (1973).

QUALTIERE & PEARSON, "Radioimmune Precipitation Study Comparing the Epstein-Barr Virus Membrane Antigens Expressed on P3HR-1 Virus-Superinfected Raji Cells to those Expressed on Cells in a B-95 Virus-Transformed Produced Culture Activated with Tumor-Promoting Agent (TPA)," *Virology* 102:360-369 (1980).

QUERY, et al., "A Common RNA Recognition Motif Identified within a Defined U1 RNA Binding of the 70K U1 snRNP Protein," *Cell* 57:89-101 (1989).

RAVIRAJAN & STAINES, "Involvement in Lupus Disease of Idiotypes Id.F-423 and Id.IV-228 Defined, Respectively, Upon Foetal and Adult MRL/Mp-lpr/lpr DNA-binding Monoclonal Autoantibodies" *Immunology* 74:342-347 (1991).

INFORMATION DISCLOSURE STATEMENT

REICHLIN, et al., "Autoantibodies to the URNP Particles: Relationship to Clinical Diagnosis and Nephritis," *Clin. Exp. Immunol.* 83:286-290 (1991).

REICHLIN, et al., "Concentration of Autoantibodies to native 60-kd Ro/SS-A and Denatured 52-kd Ro/SS-A in Eluates from the Heart of a Child Who Died with Congenital Complete Heart Block," *Arth. And Rheum.* 37:1698-1703 (1994).

RENZ, et al., "Expression of the Major Human Ribonucleoprotein (RNP) Autoantigens in *Escherichia coli* and their Use in an EIA for Screening Sera from Patients with Autoimmune Diseases," *Clin. Chem.* 35:1861-1863(1989).

REUTER, et al., "Immunization of Mice with Purified U1 Small Nuclear Ribonucleoprotein (RNP) Induces a Pattern of Antibody Specificities Characteristic of the Anti-Sm and Anti-RNP Autoimmune Response of Patients with Lupus Erythematosus, As Measured by Monoclonal Antibodies," *PNAS* 83:8689-8693 (1986).

RHODES, et al., "Autoantibodies in Infectious Mononucleosis Have Specificity for the Glycine-Alanine Repeating Region of the Epstein-Barr Virus Nuclear Antigen," *J. Exp. Med.*, 165:1026-1040 (1987).

RHODES, et al., "Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen," *J. Immunol.* 134:211-216 (1985).

ROKEACH, et al., "Primary Structure of a Human Small Nuclear Ribonucleoprotein Polypeptide as Deduced by cDNA Analysis," *J. Biol. Chem.*, 264:5024-30 (1989).

ROKEACH, et al., "Molecular Cloning of a cDNA Encoding the Human Sm-D Autoantigen," *Proc. Natl. Acad. Sci. USA* 85:4832-36 (1988).

ROSE, et al., "Genetic Regulation in Autoimmune Thyroiditis," Talal N. ed. Autoimmunology Genetic Immunologic Virologic, and Clinical Aspects. New York: Academic Press, 63-87 (1977).

ROSE, et al., "Studies on Experimental Thyroiditis," *Ann. NY Acad. Sci.* 124:201-209 (1965).

ROSE, et al., "T-Cell Regulation in Autoimmune Thyroiditis," *Immunol. Reviews* 55:229-314 (1981).

SABBATINI, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of Sm and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA I," *Eur. J. Immunol.* 23:1146-1152 (1993).

SAITO, et al., "Detection of Epstein-Barr Virus DNA by Polymerase Chain Reaction in Blood and Tissue Biopsies from Patients with Sjogren's Syndrome," *J. Exp. Med.*, 169:2191-2198 (1989).

SASAKI, et al., "In Vitro Manipulation of Human Anti-DNA Antibody Production by Anti-idiotypic Antibodies Conjugated with Neocarzinostatin," *The Journal of Immunology* 142(4):1159-1165 (1989).

SCHMAUSS, et al., "A Comparison of snRNP-Associated Sm-Autoantigens: Human N, Rat N and Human B/B (abstract)," *Nuc. Acid Res.* 17:1733-43 (1989).

SCOFIELD, "A Common Autoepitope Near the carboxyl Terminus of the 60-kD Ro Ribonucleoprotein: Sequence Similarity with a Viral Protein," *Journal of Clinical Immunology* 11(6):378-388 (1991).

SCOFIELD, "Autoimmune Thyroid Disease in Systemic Lupus Erythematosus and Sjogren's Syndrome," *Clin. Exp. Rheum.* 14:321-330 (1996).

SCOFIELD, "HLA-B27 Binding of Peptide From Its Own Sequence and Similar Peptides From Bacteria: Implications For Spondyloarthropathies," *Lancet*, 345:1542-1544 (1995).

SCOFIELD, et al., "Immunization with Short Peptides from the Sequence of the Systemic Lupus Erythematosus-Associated 60-kDa Ro Autoantigen Results in Anti-Ro Ribonucleoprotein Autoimmunity," *J. Immunology* 4059-4066 (1996).

SCOFIELD, et al., "Autoantigenicity of Ro/SSA Antigen is Related to a Nucleocapsid Protein of Vesicular Stomatitis Virus," *Proc. Natl. Acad. Sci. USA*, 88:3343-3347 (1991).

SCOFIELD, et al., "Development of the Anti-Ro Autoantibody Response in a Patient with Systemic Lupus Erythematosus," *Arthritis & Rheumatism* 39(10):1664-1688 (1996).

SCOFIELD, et al., "The Autoantigenicity of Human 60kD Ro/SSA is Related to Hormologies Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatis Virus," *Clinical Research* 38(2):316A, (1990).

SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides," *J. Gen. Virol.* 67:2253-2258 (1986).

SHARPE, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto-Immune Antigen and Specifically Reaching with Human Anti-Sm Auto-," *FEBS Lett.* 250:585-590 (1989).

SHOENFELD, et al. "Modulation of experimental SLE induced in naïve mice by a pathogenic anti-DNA idiotype (16/6 Id.)," Proceedings of the Second International Conference on Systemic Lupus Erythematosus Tokyo, Japan Professional Postgraduate Services 83 (1989).

SHOENFELD, et al., "Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE," *FASEB J.* 4:2646-2651 (1990).

INFORMATION DISCLOSURE STATEMENT

SILLIKENS, et al., "cDNA Cloning of the Human U1 snRNA-Associated A Protein: Extensive Homology Between U1 and U2 snRNP-Specific Proteins," *EMBO Journal* 6:3841-3848 (1987).

SILLIKENS, et al., "Human U1 snRNP-specific C Protein: Complete cDNA and Protein Sequence and Identification of a Multigene Family in Mammals," *Nucleic Acids Res.* 16:8307-21 (1988).

SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," *Digestive Dis. Sci.* 39:15-18 (1994).

SPRITZ, et al., "The Human U1-70K s.n. RNP Protein: cDNA Cloning, Chromosomal Localization, Expression, Alternative Splicing and RNA-binding," *Nucleic Acid Res.* 15:10373-91 (1987).

STURGESSION, et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La," *J. Immun.* 3212-3218 (1988).

SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis," *Ann. Neurol.* 17:371-377 (1985).

SUZUKI, et al., "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogeneic and Syngeneic Tumors," *J. Exp. Med.* 182:477-486 (1995).

TAKEDA, et al., "Antigenic Domains on the U1 Small Nuclear Ribonucleoprotein-associated 70kD Polypeptide; a comparison of regions selectively recognized by Human and Mouse Autoantibodies and by Monoclonal Antibodies," *Chem. Abstracts* 116(1): ab. No. 4803a (January 6, 1992).

TAN, et al., "The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus," *Arthritis Rheum.* 25:1271-1277 (1982).

TAN, et al., "Characteristics of a Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus," *J. Immunol.* 96:464-471 (1966).

TATEISHI, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome," *Arthritis Rhuem.* 36:827-835 (1993).

The Medical Letter on Drugs and Therapeutics 37(951):55-57 (June 23, 1995).

THEISSEN, et al., "Cloning of the Human cDNA for the U1 RNA-associated 70K Protein," *EMBO J.* 5:3209-17 (1986).

INFORMATION DISCLOSURE STATEMENT

TIGHE, Production of Human Rheumatoid Factors (RF) by SCID Mice Transplanted with Synovial Membrane Lymphocytes, presented at the Arthritis Foundation Fellows Conference, Amelia Island, Plantation, Florida, December 8-10 (1989).

TINCANI, et al., "Induction of Experimental SLE in Naive Mice by Immunization with Human Polyclonal anti-DNA Antibody Carrying the 16/6 Idiotypic," *Clinical and Exp. Rheum.* 11:129-134 (1993).

TODA, et al., "Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation," In Lacrimal Gland, Tear Film, and Dry Eye Syndrome. (D.A. Sullivan, ed.) pp. 647-650 (Plenum Press, New York 1994).

TSAI, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus," *Int. Arch. Allergy Immunol.* 106:235-240 (1995).

TSUZUKA, et al., "Lupus Autoantibodies to Double-stranded DNA Cross-react with Ribosomal Protein S1<sup>1,2</sup>," *J. Immunol.* 156:1668-1675 (1996).

TZARTOS, et al., "The Main Immunogenic region of the Acetylcholine Receptor. Structure and Role in Myasthenia Gravis," *Autoimmunity* 8:259-270 (1991).

VAN DAM, et al., "Cloned Human snRNP Proteins B and B' Differ Only in Their Carboxy-Terminal Part," *EMBO J.* 8(12):3853-3860 (1989).

VAN VENROOIJ, et al., "B Cell Epitopes on Nuclear Autoantigens," *Arthritis and Rheumatism* 37(5):608-616 (1994).

VANDENBARK, et al., "Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide," *Immunology and Cell Biology* 76:83-90 (1998).

VENABLES, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome," *Clin. Exp. Immunol.*, 75:359-364 (1989).

VENABLES, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome," *J. Autoimmunity* 2:439-448 (1989).

VIRJI & HECKELS, "Location of a Blocking Epitope on Outer-membrane Protein III of *Neisseria Gonorrhoeae* by Synthetic Peptide Analysis," *J. Gen. Microbiol.* 135:1895-1899 (1989).

VOLLER & BIDWELL, "Enzyme-Linked Immunosorbent Assay," Manual of Clinical Laboratory Immunology (Chapter 17) (1986).

INFORMATION DISCLOSURE STATEMENT

WAGSTAFF, et al., "Aciclovir - A Reappraisal of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy," *Drugs* 47:153-205 (1994).

WAITE, et al., "Anti-Jo-1 antibodies are Directed at an Evolutionarily-conserved Conformational Site on Human Histidyl-tRNA Synthetase," *Mol. Cell Biol. Autoantibodies Autoimm.* 100-101 (1989).

WALTUCK & BUYON, "Autoantibody-associated Congenital Heart Block: Outcome in Mothers and Children," *Ann. Intern. Med.* 120:544-551 (1994).

WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," *Med. Hypotheses* 25:93-97 (1988).

WATSON, et al., "Certain Properties Make Substances Antigenic," in Molecular Biology of the Gene, Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).

WHITTINGHAM, et al., "Epstein-Barr Virus as an Etiological Agent in Primary Sjogren's Syndrome," *Med. Hypothesis*, 22:373-386 (1987).

WILLIAMS, et al., "A Repeated Proline-rich Sequence in Sm B/B' and N is a Dominant Epitope Recognized by Human and Murine Autoantibodies," *J. Autoimmunity* 3:715-725 (1990).

WILSON, et al., "Association of Lymphomatoid Granulomatosis With Epstein-Barr Viral Infection of B Lymphocytes and Response to Interferon- $\alpha$ 2b," *Blood*, 87:4531-4537 (1996).

WINFIELD, et al., "Serologic Studies in patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction," *Arthritis Rheum.* 21:289-294 (1978).

WITEBSKY, et al., "Chronic Thyroiditis and Autoimmunization," *J. Am. Med. Assoc.* 164:1439-1447 (1957).

XIE & SNYDER, "Two Short Autoepitopes on the Nuclear Dot Antigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus," *Proc. Natl. Acad. Sci.* 92:1639-1643 (1995).

YAMAMOTO, et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," *J. Immun.* 140:311-317 (1988).

YOKOCHI, et al., "Hight Titer of Antibody to the Epstein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," *J. Rheumatol.* 16:1029-1032 (1989).

YU, et al. "Molecular Mimicry in HLA-B-27-Related Arthritis," *Annals of Internal Medicine* 111(7):581-591 (1989).

U.S.S.N.: Divisional of 10/012,756  
Filed: June 27, 2003  
INFORMATION DISCLOSURE STATEMENT

ZELLER, et al., "Nucleocytoplasmic Distribution of snRNPs and Stockpiled snRNA-Binding Proteins During Oogenesis and Early Development in *Xenopus laevis*," *Cell* 32:425-434 (1983).

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



---

Patrea L. Pabst  
Reg. No. 31,284

Dated: June 27, 2003

HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400  
404-817-8473  
FAX 404-817-8588  
www.hklaw.com  
ATL1 #582633 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
				Application Number	Divisional of 10/012,756
				Filing Date	June 27, 2003
				First Named Inventor	John B. Harley
				Group Art Unit	
				Examiner Name	
Sheet	1	of	23	Attorney Docket Number	OMRF 161 DIV (2)

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,554,101		Hopp	11-19-1985	
		4,654,419		Vaughan	03-31-1987	
		4,707,358		Kieff	11-17-1987	
		4,784,942		Harley	11-15-1988	
		4,865,970		Brot, et al.	09-12-1989	
		5,312,752		Woltz, et al.	05-17-1994	
		5,354,691		Van Eden, et al.	10-11-1994	
		5,637,454		Harley	06-10-1987	
		5,679,774		Wolf	10-21-1997	
		5,723,283		Classen	03-03-1998	
		5,726,286		Alderson	03-10-1998	
		5,874,531		Strominger, et al.	02-23-1999	
		5,965,353		Middeldorp	10-12-1999	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		EP	0 113 431		Yeshiva University	07-18-1984	
		EP	0 313 156		Akzo N.V.	04-26-1989	
		PCT	WO 86/01210		Scripps Clinic Res.	02-27-1986	
		PCT	WO 88/09932		Amrad Corporation Ltd.	06-03-1988	
		PCT	WO 91/11718		Board of Regents of the University of Oklahoma	08-08-1991	
		PCT	WO 91/17171		Oklahoma Medical Research Foundation	11-14-1991	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<p>Completeness Known</p>	
		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	OMRF 161 DIV (2)
Sheet	2	of	23

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		PCT	WO 91/18920		Neosystem	12-12-1991		
		PCT	WO 93/21223		Board of Regents of the University of Oklahoma	10-28-1993		
		PCT	WO 94/02445		Yeda Research and Development Co. Ltd.	02-03-1994		
		PCT	WO 94/02509		Rijksuniversiteit Leiden	02-03-1994		
		PCT	WO 94/06912		Middeldorp	03-31-1994		
		PCT	WO 94/21669		Medclone, Inc.	09-29-1994		

<div[](https://imgur.com/3DfJGZB.png)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	3	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examine  
Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	4	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ALEXANDER, et al., "Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, and Experimental Model," <i>Arth. And Rheum.</i> 35:176-189 (1992).	
		ARBUCKLE, et al., "Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus," <i>Scand. J. Immunol.</i> 50(5):447-55 (1999).	
		BANERJEE, et al., "Complete Nucleotide Sequence of the mRNA Coding for the N Protein of Vesicular Stomatitis Virus (New Jersey Serotype)," <i>Virology</i> 137:432-438 (1984).	
		BARAKET, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," <i>Clin. Exp. Immunol.</i> 89:38-45 (1992).	
		BARAKET, et al., "Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera," <i>Clin. Exp. Immunol.</i> 86:71-78 (1991).	
		BARAKET, et al., "Recognition of Synthetic Peptides of Sm-D Autoantigen by Lupus Sera," <i>Clin. Exp. Immunol.</i> 81:256-262 (1990).	
		BEN-CHETRIT, et al., "Isolation and Characterization of a cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," <i>J. Clin. Inv.</i> 83:1284-1292 (1989).	
		BLANK, et al., "Induction of Experimental Anti-phospholipid Syndrome Associated with SLE Following Immunization with Human Monoclonal Pathogenic Anti-DNA Idiotype," <i>J. Autoimmunity</i> 5:495-509 (1992).	
		BLANK, et al., "Induction of SLE-Like Disease in Naive Mice with a Monoclonal anti-DNA Antibody Derived from a Patient with Polymyositis carrying the 16/6 id," <i>J. Autoimmunity</i> 1:683-591 (1988).	
		BLANK, et al., "Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody SA-1 (16/6 id+) and for Mouse Tuberculosis Antibody TB/68 (16/6 id+)" <i>Clin. Immunol. Immunopathol.</i> 60:471-483 (1991).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
Filing Date	June 27, 2003		
First Named Inventor	John B. Harley		
Group Art Unit			
Examiner Name			
Sheet	5	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		BLANK, et al., "Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti-DNA Idiotype in Naive Mice," <i>J. Rheumatol.</i> 17:311-317 (1990).
		BLANK, et al., "The Effect of the Immunomodulator Agent AS101 on Interleukin-2 Production in Systemic Lupus Erythematosus (SLE) Induced in Mice by Pathogenic Anti-DNA Antibody," <i>Clin. Exp. Immunol.</i> 79:443-447 (1990).
		BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," <i>Arch. Neurol.</i> 42:1798-1804 (1992).
		BRAY, et al., "Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis," <i>Arch. Neurology</i> 40:406-408 (1983).
		BUYON, "Neonatal Lupus Syndrome," <i>Curr. Opin. In Rheum.</i> 6:523-529 (1994).
		CHAMBERS, et al., "Genomic Structure and Amino Acid Sequence domains of the Human La Autoantigen," <i>J. Biol. Chem.</i> 263:18043-18051 (1988).
		CHAMBERS, et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 82:2115-2119 (1985).
		CHAN, et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," <i>Nucl. Acids Res.</i> 17:2233-2244 (1989).
		COHEN, "The Self, the World and Autoimmunity - Autoimmunity - In Which the Immune System Recognizes and Attacks the Self's Own Tissues - Is Not as Simple as it Seemed. Self-recognition Appears to be at the Heart of Health as Well as of Certain Diseases," <i>Scientific American</i> 258:52-60 (1988).
		CRAFT, et al., "Murine and Drosophila B Proteins of SM snRNPs," <i>Mol. Biol. Rep.</i> 15:159 (1991).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Completeness Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	6	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published <sup>2</sup>
		CRONE, et al., "Viral Transcription is Necessary and Sufficient for Vesicular Stomatitis Virus to Inhibit Maturation of Small Nuclear Ribonucleoproteins," <i>Journal of Virology</i> 63(10):4172-4180 (1989).
		CUNNINGHAM, et al., "Human Monoclonal Antibodies Reactive with Antigens of the Group A Streptococcus and Human Heart," <i>Journal of Immunology</i> 141(8):2760-2766 (1988).
		DALLDORF, et al., "The Lymphomas of Brazilian Children," <i>J. Am. Med. Assn.</i> 208:1365-8 (1969).
		DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," <i>J. Pathol.</i> 163:351-360 (1991).
		DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," <i>Am J. Med.</i> 92:453-454 (1992).
		DEPOLO, et al., "Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering Particles," <i>J. of Virology</i> 61:454-464 (1987).
		DEUTSCHER, et al., "Molecular Analysis of the 60-kDa Human Ro Ribonucleoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 85:9479-83 (1988).
		DICKEY, "Human Autoantibody Producing Grafts in SCID Mice," presented to the Oklahoma Lups Association, Inc., Sept. 1, 1989.
		DYRBERG & OLDSSTONE, "Peptides as Probes to Study Molecular Mimicry and Virus-Induced Autoimmunity," <i>Current Topics in Microbiology and Immunology</i> 130:25-37 (1986).
		ELKON, et al., "Epitope Mapping of Recombinant HeLa SmB and B' Peptides Obtained by the Polymerase Chain Reaction," <i>J. Immun.</i> 145:636-643 (1990).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complaint if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Serial No. of 10/012,756
Sheet	7	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		ESQUIVEL, et al., "Induction of Autoimmunity in Good and Poor Responder Mice with Mouse Thyroglobulin and Lipopolysaccharide," <i>J. Exp. Med.</i> 145:1250-1263 (1977).
		EVANS & NIEDERMAN, "Epstein-Barr virus" in <i>Viral Infections in Humans</i> , 3rd ed. Evans, A.S. ed. pp 265-292 (Plenum, New York City 1989).
		EVANS & ROTHFIELD, "E.B. Virus and Other Viral Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 1:1127-1128 (1973).
		EVANS, "E.B. Virus Antibody in Systemic Lupus Erythematosus" <i>Lancet</i> 1:1023-4 (1971).
		EVANS, et al., "Raised Antibody Titres to E.B. Virus in Systemic Lupus Erythematosus," <i>Lancet</i> 1:167-168 (1971).
		FERRIS & DONALDSON, <i>Veterinary Microbiology</i> 18(3-4):243-258 (1988).
		FINERTY, et al., "Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," <i>Vaccine</i> 12:1180-1184 (1994).
		FINERTY, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector," <i>J. Gen. Virol.</i> 73:449-453 (1992).
		FOX, "Sjogren's Syndrome," <i>Current Opin. Rheum.</i> 7:409-416 (1995).
		FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," <i>J. Immunol.</i> 137:3162-3168 (1986).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complaint If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	Divisional 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	8	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," <i>J. Rheumatol.</i> 19:18-24 (1992).
		FRICKE, et al., "Induction of Experimental Systemic Lupus Erythematosus in Mice by Immunization with a Monoclonal Anti-La Autoantibody," <i>Intern. Immunol.</i> 2:225-230 (1990).
		FRITZ, et al., "Small Nuclear U-Ribonucleoproteins in <i>Xenopus Laevis</i> Development," <i>J. Mol. Biol.</i> 178:273-285 (1984).
		GAITHER, et al., "Implications of Anti-Ro/Sjogren's Syndrome a Antigen Autoantibody in Normal Sera for Autoimmunity," <i>J. Clin. Invest.</i> 79:841-846 (1987).
		GAITHER, et al., "Affinity Purification and Immunoassay of Anti-Ro/SSA" <i>Peptides Biol. Fluids</i> 33:413-416 (1985).
		GALLIONE, et al., "Nucleotide Sequences of the mRNA's Encoding the Vesicular Stomatitis Virus N and NS Proteins," <i>Virology</i> 39:529-535 (1981).
		GAUTAM, et al., "A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis," <i>J. Immunol.</i> 161:60-64 (1998).
		GERGELY, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 1:325-326 (1973).
		GEYSEN, et al., "Strategies for Epitope Analysis Using Peptide Synthesis," <i>J. of Immunol. Meth.</i> 102:259-274 (1987).
		GEYSEN, et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002 (1984).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Completeness Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number <b>Divisional of 10/012,756</b>	
		Filing Date <b>June 27, 2003</b>	
		First Named Inventor <b>John B. Harley</b>	
		Group Art Unit	
		Examiner Name	
Sheet	9	of	23
		Attorney Docket Number <b>OMRF 161 DIV (2)</b>	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		GRABOWSKI, et al., "Drosophila AP3, a Presumptive DNA Repair Protein, is Homologous to Human Ribosomal Associated Protein PO," <i>Nucleic Acids Research</i> 19(15):4297 (1991).	
		GU, et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," <i>Dev. Biol. Stand.</i> 84:171-177 (1995).	
		GULDNER, et al., "Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera." <i>The Journal of Immunology</i> 141(2):469-475 (1988).	
		GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," <i>Cancer Res.</i> 56:969-972 (1996).	
		HAAHR, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease," <i>Ann. N. Y. Acad. Sci.</i> 724:148-156 (1996).	
		HAHN, "Suppression of Autoimmune Diseases with Anti-idiotypic Antibodies: Murine Lupus Nephritis as a Model" <i>Springer Seminars in Immunopathology</i> , 7(1):25-34 (1984).	
		HARDGRAVE, et al., "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," <i>Arthritis and Rheumatism</i> 36(7):962-970 (1993).	
		HARLEY & GAITHER, "Autoantibodies" <i>Rheum. Dis. Clin. N. Amer.</i> 14:43-56 (1992).	
		HARLEY & JAMES, "Review Articles: Autoepitopes in Lupus," <i>J. Lab. Clin. Med.</i> 126(6):509-516 (1995).	
		HARLEY, et al., "Gene Interaction at HLA-DQ Enhances Autoantibody Production in Primary Sjogren's Syndrome," <i>Science</i> 232:1145-1147 (1986).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	10	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		HARLEY, et al., "Anti-Ro (SS-A) and Anti-La (SS-B) in Patients with Sjogren's Syndrome," <i>Arthritis Rheum.</i> 29:196-206 (1986).
		HARLEY, et al., "Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers," <i>Arthritis Rheum.</i> 42(8):1782-3 (1999).
		HERBERT, et al., Dictionary of Immunology 3 <sup>rd</sup> Ed. Blackwell Scientific Publications Oxford UK page 14 (1985).
		HESLOP, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes," <i>Nature Med.</i> 2:551-555 (1996).
		HINTERBERGER, "Isolation of Small Nuclear Ribonucleoproteins Containing U1, U2, U4, U5, and U6 RNAs," <i>J. Biol. Chem.</i> 258:2604-2613 (1983).
		HOLLINGER, et al., "Seroepidemiologic Studies in Systemic Lupus Erythematosus," <i>Bact. Proc.</i> 131:174 (1970).
		HORSFALL, et al., "Ro and La Antigens and Maternal Anti-La Idiotype on the Surface of Myocardial Fibers in Congenital heart Block," <i>J. of Autoimmun.</i> 4:165-176 (1991).
		HUANG, et al., "Human Anti-Ro Autoantibodies Bind Peptides Accessible to the Surface of the Native Ro Autoantigen," <i>Scand. J. Immunol.</i> 41:220-228 (1995).
		HUANG, et al., "Immunization with Vesicular Stomatitis Virus Nucleocapsid Protein induces Autoantibodies to the 60 kD Ro Ribonucleoprotein Particle," <i>J. Invest. Med.</i> 43:151-158 (1995).
		HURD, et al., "Formation of Leukocyte Inclusions in Normal Polymorphonuclear Cells Incubated with Synovial Fluid," <i>Arthritis Rheum.</i> 13:724-733 (1970).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complaint if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	Divisional fil 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	11	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		INOUE, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis," <i>J. Infect. Dis.</i> 164:22-28 (1991).
		ISHII, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection," <i>Immunol. Cell Biol.</i> 73:463-468 (1995).
		JAMES & HARLEY, "Human Lupus Anti-Spliceosome A Protein Autoantibodies Bind Contiguous Surface Structures and Segregate into Two Sequential Epitope Binding Patterns," <i>J. Immunol.</i> 4018-4026 (1994).
		JAMES & HARLEY, "A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice," <i>J. Immunol.</i> 160(1):502-8 (1998).
		JAMES & HARLEY, "Linear Epitope Mapping of an Sm B/B' Polypeptide," <i>J. Immunol.</i> 148:2074-2079 (1992).
		JAMES & HARLEY, "Peptide Autoantigenicity of the Small Nuclear Ribonucleoprotein C," <i>Clin. And Exp. Rheum.</i> 13:299-305 (1995).
		JAMES & HARLEY, "Sequential Fine Specificity of the Small Nuclear Ribonuclear Protein C," <i>Clinical Res.</i> 41(2):PA393 (1993).
		JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," <i>J. Exp. Med.</i> 181:453-461 (1995).
		JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," <i>J. Clin. Invest.</i> 100:3019-26 (1997).
		JAMES, et al., "Basic Amino Acids Predominate in the Sequential Autoantigenic Determinants of the Small Nuclear 70K Ribonucleoprotein," <i>Scand. J. Immunol.</i> 39:557-566 (1994).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	12	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		JAMES, et al., "Inbred Mice Strains Differ in Their Capacity to Develop Spliceosomal Autoimmunity After Peptide Immunization," <i>Arthritis Rheum.</i> 38:S226 (1995).
		JAMES, et al., "Lupus Humoral Autoimmunity After Short Peptide Immunization," <i>Arthritis Rheum.</i> 39:S216 (1996).
		JAMES, et al., "Lupus humoral autoimmunity after short peptide immunization," <i>Ann. N. Y. Acad. Sci.</i> 815:124-7 (1997).
		JAMES, et al., "Sequential Autoantigenic Determinants of the Small Nuclear Ribonucleoprotein Sm D Shared by Human Lupus Autoantibodies and MRL lpr/lpr Antibodies," <i>Clin. Exp. Immunol.</i> 98:419-426 (1994).
		KALUSH, et al., "Neonatal Lupus Erythematosus with Cadian Involvement in Offspring of Mothers with Experimental Systemic Lupus Erythematosus," <i>J. of Clin. Immunol.</i> 14:314-321 (1994).
		KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 10:327-332 (1992).
		KAUFMAN, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Anklosing spondylitis Pathogenesis," <i>Arthritis Rheum.</i> 39:S298 (1996).
		KIEFF & LIEBOWITZ, Epstein-Barr virus and its replication. In <i>Virology</i> , 2nd ed. Fields et al., eds. pp 1889-1921 (Raven Press, New York 1990).
		KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," <i>Immunol. Lett.</i> 17:249-252 (1988).
		KLIPPEL, et al., "Epstein-Barr Virus Antibody and Lymphocyte Tubuloreticular Structures in Systemic Lupus Erythematosus," <i>Lancet</i> , 2:1057-1058 (1973).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complaint If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	13	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		KURILLA, et al., "The Leader RNA of Vesicular Stomatitis Virus is Bound by a Cellular Protein Reactive with Anti-La Lupus Antibodies," <i>Cell</i> 34:837-845 (1983).
		KUZUSHIMA, et al., "Establishment of Anti-Epstein-Barr Virus (EBV) Cellular Immunity by Adoptive Transfer of Virus-Specific Cytotoxic T Lymphocytes from an HLA-matched Sibling to a Patient with Severe chronic Active EBV Infection," <i>Clin. Exp. Immunol.</i> 103:192-198 (1996).
		LARSEN, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis," <i>Neurology</i> 35:435-438 (1985).
		LAZAROVITS, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation," <i>Clin. Invest. Med.</i> 17:621-625 (1994).
		LEE, et al., "Cardiac Immunoglobulin Deposition in Congenital heart Block Associated with Maternal Anti-Ro Autoantibodies," <i>Am. J. of Med.</i> 83:793-796 (1987).
		LEE, et al., "The Recognition of Human 60-kDa Ro Ribonucleoprotein Particles by Antibodies Associated with Cutaneous Lupus and Neonatal Lupus," <i>J. Investigative Dermatology</i> 107(1):225-228 (1996).
		LEFF, "Maverick Herpes Receptor Sparks Search for KS Drug," <i>Bio World Today</i> 8(17):1 (1997).
		LEHMAN, et al., "Spreading of T-Cell Autoimmunity to Cryptic Determinants of an Autoantigen," <i>Nature</i> 356:155-157 (1992).
		LERNER & STEITZ, "Antibodies to Small Nuclear RNAs Complexed with Proteins are Produced by Patients with Systemic Lupus Erythematosus," <i>Proc. Natl. Acad. Sci. USA</i> 76:5495-5499 (1979).
		LERNER, et al., "Are snRNPs Involved in Splicing?" <i>Nature</i> 283:220-224 (1980).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	14	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," <i>Nature</i> 375:685-688 (1995).	
		MADDISON, et al., "Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Antigens in SLE," <i>Arthritis Rheum.</i> 20:819-824 (1977).	
		MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," <i>Am. J. Med.</i> 96:97 (1994).	
		MANFREDI, et al., "Molecular Anatomy of an Autoantigen: T and B Epitopes on the Nicotinic Acetylcholine Receptor in Myasthenia Gravis," <i>J. Lab. Clin. Med.</i> 120:13-21 (1992).	
		MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by <i>in Situ</i> Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," <i>Am. J. Med.</i> 90:286-294 (1991).	
		MATTER, et al., "Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies," <i>Arthritis Rheum.</i> 25:1278-1283 (1982).	
		MATTIOLI, et al. "Physical Association of Two Nuclear Antigens and Mutual Occurrence of Their Antibodies: The relationship of the SM and RNA protein (MO) Systems in SLE Sera," <i>J. Immunol.</i> 110:1318-1324 (1973).	
		MCALLISTER, et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential Sm Epitope," <i>EMBO J.</i> 8:1177-1181 (1989).	
		MENDLOVIC, et al., "Induction of an SLE-Like Disease in Mice by a Common Anti-DNA Idiotype," <i>Proc. Natl. Acad. Sci. USA</i> 85:2260-2264 (1988).	
		MENDLOVIC, et al., "The Genetic Regulation of the Induction of Experimental SLE," <i>Immunology</i> 69:228-236 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	15	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		MENDLOVIC, et al., "The Role of Anti-Idiotypic Antibodies in the Induction of Experimental Systemic Lupus Erythematosus in Mice," <i>Eur. J. Immunol.</i> 19:729-732 (1989).
		MILLER, et al., "The Role of an Autoantigen, Histidyl-tRNA Synthetase, in the Induction and Maintenance of Autoimmunity," <i>Proc. Natl. Acad. Sci. USA</i> 87:9933-9937 (1990).
		MIYASHITA, et al., "A Novel Form of Epstein-Barr Virus Latency in Normal B Cells In Vivo," <i>Cell</i> , 80:593-601 (1995).
		MORGAN, "Epstein-Barr Virus Vaccines," <i>Vaccine</i> 10:563-571 (1992).
		MORGAN, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," <i>J. Med. Virol.</i> 29:74-78 (1989).
		MORLAND, et al., "Anti-idiotype and Immunosuppressant Treatment of Murine Lupus," <i>Clin. Exp. Immunol.</i> 83(1):126-132 (1991).
		MORSHED, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients," <i>Gastroenterol. Jpn.</i> 27(6):751-758 (1992).
		MOSIER, et al., "Transfer of a functional human immune system to mice with severe combined immunodeficiency," <i>Nature</i> 335:256-259 (1988).
		MUNVES, et al., "Antibodies to Sm and RNP," <i>Arthritis Rheum.</i> 26:848-853 (1983).
		NEWELL & STEVENS, "E.B. Virus Antibody in Systemic Lupus Erythematosus," <i>Lancet</i> 1:652 (1971).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	16	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," <i>Br. J. Rheum.</i> 33:317-322 (1994).	
		NICHOLSON, "A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens," <i>Proc. Natl. Acad. Sci. USA</i> 94:9279-9284 (1997).	
		OHOSONE, et al., "Molecular Cloning of cDNA Encoding Sm Autoantigen: Derivation of a cDNA for a B Polypeptide of the U Series of Small Nuclear Ribonucleoprotein Particles," <i>Proc. Natl. Acad. Sci. USA</i> 86:4249-4253 (1989).	
		PALFI, et al., "Purification of the Major UsnRNPs from Broad Bean Nuclear Extracts and Characterization of their Protein Constituents," <i>Nucleic Acids Res.</i> 17:1445-1458 (1989).	
		PETERSEN, et al., "Altered Immune Response to Glycine-Rich Sequences of Epstein-Barr Nuclear Antigen-1 in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 33:993-1000 (1990).	
		PETTERSSON, et al., "The Structure of Mammalian Small Nuclear Ribonucleoproteins," <i>J. Biol. Chem.</i> 259:5907-5914 (1984).	
		PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," <i>Ophthalmology</i> 97:976-984 (1990).	
		PFLUGFELDER, et al., "Epstein-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," <i>Am. J. Pathol.</i> 143:49-64 (1993).	
		PHILLIPS & CHRISTIAN, "Myxovirus Antibody Increases in Human Connective Tissue Disease," <i>Science</i> 168:982-4 (1970).	
		PHILLIPS, et al., "Viruses and Systemic Lupus Erythematosus," <i>Lancet</i> 1:1449 (1973).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	17	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		QUALTIERE & PEARSON, "Radioimmune Precipitation Study Comparing the Epstein-Barr Virus Membrane Antigens Expressed on P3HR-1 Virus-Superinfected Raji Cells to those Expressed on Cells in a B-95 Virus-Transformed Producer Culture Activated with Tumor-Promoting Agent (TPA)," <i>Virology</i> 102:360-369 (1980).	
		QUERY, et al., "A Common RNA Recognition Motif Identified within a Defined U1 RNA Binding of the 70K U1 snRNP Protein," <i>Cell</i> 57:89-101 (1989).	
		RAVIRAJAN & STAINES, "Involvement in Lupus Disease of Idiotypes Id.F-423 and Id.IV-228 Defined, Respectively, Upon Foetal and Adult MRL/Mp-lpr/lpr DNA-binding Monoclonal Autoantibodies" <i>Immunology</i> 74:342-347 (1991).	
		REICHLIN, et al., "Autoantibodies to the URNP Particles: Relationship to Clinical Diagnosis and Nephritis," <i>Clin. Exp. Immunol.</i> 83:286-290 (1991).	
		REICHLIN, et al., "Concentration of Autoantibodies to native 60-kd Ro/SS-A and Denatured 52-kd Ro/SS-A in Eluates from the Heart of a Child Who Died with Congenital Complete Heart Block," <i>Arth. And Rheum.</i> 37:1698-1703 (1994).	
		RENZ, et al., "Expression of the Major Human Ribonucleoprotein (RNP) Autoantigens in <i>Escherichia coli</i> and their Use in an EIA for Screening Sera from Patients with Autoimmune Diseases," <i>Clin. Chem.</i> 35:1861-1863 (1989).	
		REUTER, et al., "Immunization of Mice with Purified U1 Small Nuclear Ribonucleoprotein (RNP) Induces a Pattern of Antibody Specificities Characteristic of the Anti-Sm and Anti-RNP Autoimmune Response of Patients with Lupus Erythematosus, As Measured by Monoclonal Antibodies," <i>PNAS</i> 83:8689-8693 (1986).	
		RHODES, et al., "Autoantibodies in Infectious Mononucleosis Have Specificity for the Glycine-Alanine Repeating Region of the Epstein-Barr Virus Nuclear Antigen," <i>J. Exp. Med.</i> 165:1026-1040 (1987).	
		RHODES, et al., "Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen," <i>J. Immunol.</i> 134:211-216 (1985).	
		ROKEACH, et al., "Primary Structure of a Human Small Nuclear Ribonucleoprotein Polypeptide as Deduced by cDNA Analysis," <i>J. Biol. Chem.</i> , 264:5024-30 (1989).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
Sheet	18	of	23
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published <sup>T<sup>2</sup></sup>
		ROKEACH, et al., "Molecular Cloning of a cDNA Encoding the Human Sm-D Autoantigen," <i>Proc. Natl. Acad. Sci. USA</i> 85:4832-36 (1988).
		ROSE, et al., "Genetic Regulation in Autoimmune Thyroiditis," Talal N. ed. <i>Autoimmunology Genetic Immunologic Virologic, and Clinical Aspects</i> . New York: Academic Press, 63-87 (1977).
		ROSE, et al., "Studies on Experimental Thyroiditis," <i>Ann. NY Acad. Sci.</i> 124:201-209 (1965).
		ROSE, et al., "T-Cell Regulation in Autoimmune Thyroiditis," <i>Immunol. Reviews</i> 55:229-314 (1981).
		SABBATINI, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AnD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA I," <i>Eur. J. Immunol.</i> 23:1146-1152 (1993).
		SAITO, et al., "Detection of Epstein-Barr Virus DNA by Polymerase Chain Reaction in Blood and Tissue Biopsies from Patients with Sjogren's Syndrome," <i>J. Exp. Med.</i> , 169:2191-2198 (1989).
		SASAKI, et al., "In Vitro Manipulation of Human Anti-DNA Antibody Production by Anti-idiotypic Antibodies Conjugated with Neocarzinostatin," <i>The Journal of Immunology</i> 142(4):1159-1165 (1989).
		SCHMAUSS, et al., "A Comparison of snRNP-Associated Sm-Autoantigens: Human N, Rat N and Human B/B (abstract)," <i>Nuc. Acid Res.</i> 17:1733-43 (1989).
		SCOFIELD, "A Common Autoepitope Near the carboxyl Terminus of the 60-kD Ro Ribonucleoprotein: Sequence Similarity with a Viral Protein," <i>Journal of Clinical Immunology</i> 11(6):378-388 (1991).
		SCOFIELD, "Autoimmune Thyroid Disease in Systemic Lupus Erythematosus and Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 14:321-330 (1996).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
Sheet 19 of 23	Examiner Name		
Sheet 19 of 23	Attorney Docket Number	OMRF 161 DIV (2)	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		SCOFIELD, "HLA-B27 Binding of Peptide From Its Own Sequence and Similar Peptides From Bacteria: Implications For Spondyloarthropathies," <i>Lancet</i> , 345:1542-1544 (1995).
		SCOFIELD, et al., "Immunization with Short Peptides from the Sequence of the Systemic Lupus Erythematosus-Associated 60-kDa Ro Autoantigen Results in Anti-Ro Ribonucleoprotein Autoimmunity," <i>J. Immunology</i> 4059-4066 (1996).
		SCOFIELD, et al., "Autoantigenicity of Ro/SSA Antigen is Related to a Nucleocapsid Protein of Vesicular Stomatitis Virus," <i>Proc. Natl. Acad. Sci. USA</i> , 88:3343-3347 (1991).
		SCOFIELD, et al., "Development of the Anti-Ro Autoantibody Response in a Patient with Systemic Lupus Erythematosus," <i>Arthritis &amp; Rheumatism</i> 39(10):1664-1688 (1996).
		SCOFIELD, et al., "The Autoantigenicity of Human 60kD Ro/SSA is Related to Homologies Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatitis Virus," <i>Clinical Research</i> 38(2):316A, (1990).
		SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides," <i>J. Gen. Virol.</i> 67:2253-2258 (1986).
		SHARPE, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto-Immune Antigen and Specifically Reacting with Human Anti-Sm Auto-," <i>FEBS Lett.</i> 250:585-590 (1989).
		SHOENFELD, et al. "Modulation of experimental SLE induced in naïve mice by a pathogenic anti-DNA idiotype (16/6 Id.)," <i>Proceedings of the Second International Conference on Systemic Lupus Erythematosus Tokyo, Japan Professional Postgraduate Services 83</i> (1989).
		SHOENFELD, et al., "Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE," <i>FASEB J.</i> 4:2646-2651 (1990).
		SILLIKENS, et al., "cDNA Cloning of the Human U1 snRNA-Associated A Protein: Extensive Homology Between U1 and U2 snRNP-Specific Proteins," <i>EMBO Journal</i> 6:3841-3848 (1987).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional f 10/012,756
Sheet	20	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published <sup>T<sup>2</sup></sup>
		SILLIKENS, et al., "Human U1 snRNP-specific C Protein: Complete cDNA and Protein Sequence and Identification of a Multigene Family in Mammals," <i>Nucleic Acids Res.</i> 16:8307-21 (1988).
		SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," <i>Digestive Dis. Sci.</i> 39:15-18 (1994).
		SPRITZ, et al., "The Human U1-70K s.n. RNP Protein: cDNA Cloning, Chromosomal Localization, Expression, Alternative Splicing and RNA-binding," <i>Nucleic Acid Res.</i> 15:10373-91 (1987).
		STURGESSION, et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La," <i>J. Immun.</i> 32:12-3218 (1988).
		SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis," <i>Ann. Neurol.</i> 17:371-377 (1985).
		SUZUKI, et al., "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogeneic and Syngeneic Tumors," <i>J. Exp. Med.</i> 182:477-486 (1995).
		TAKEDA, et al., "Antigenic Domains on the U1 Small Nuclear Ribonucleoprotein-associated 70kD Polypeptide; a comparison of regions selectively recognized by Human and Mouse Autoantibodies and by Monoclonal Antibodies," <i>Chem. Abstracts</i> 116(1): ab. No. 4803a (January 6, 1992).
		TAN, et al., "The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 25:1271-1277 (1982).
		TAN, et al., "Characteristics of a Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus," <i>J. Immunol.</i> 96:464-471 (1966).
		TATEISHI, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome," <i>Arthritis Rhuem.</i> 36:827-835 (1993).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	21	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		The Medical Letter on Drugs and Therapeutics 37(951):55-57 (June 23, 1995).
		THEISSEN, et al., "Cloning of the Human cDNA for the U1 RNA-associated 70K Protein," EMBO J. 5:3209-17 (1986).
		TIGHE, Production of Human Rheumatoid Factors (RF) by SCID Mice Transplanted with Synovial Membrane Lymphocytes, presented at the Arthritis Foundation Fellows Conference, Amelia Island, Plantation, Florida, December 8-10 (1989).
		TINCANI, et al., "Induction of Experimental SLE in Naive Mice by Immunization with Human Polyclonal anti-DNA Antibody Carrying the 16/6 Idiotype," Clinical and Exp. Rheum. 11:129-134 (1993).
		TODA, et al., "Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation," In Lacrimal Gland, Tear Film, and Dry Eye Syndrome. (D.A. Sullivan, ed.) pp. 647-650 (Plenum Press, New York 1994).
		TSAI, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus," Int. Arch. Allergy Immunol. 106:235-240 (1995).
		TSUZUKA, et al., "Lupus Autoantibodies to Double-stranded DNA Cross-react with Ribosomal Protein S1 <sup>2</sup> ," J. Immunol. 156:1668-1675 (1996).
		TZARTOS, et al., "The Main Immunogenic region of the Acetylcholine Receptor. Structure and Role in Myasthenia Gravis," Autoimmunity 8:259-270 (1991).
		VAN DAM, et al., "Cloned Human snRNP Proteins B and B' Differ Only in Their Carboxy-Terminal Part," EMBO J. 8(12):3853-3860 (1989).
		VAN VENROOIJ, et al., "B Cell Epitopes on Nuclear Autoantigens," Arthritis and Rheumatism 37(5):608-616 (1994).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional of 10/012,756
		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	22	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		VANDENBARK, et al., "Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide," <i>Immunology and Cell Biology</i> 76:83-90 (1998).
		VENABLES, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome," <i>Clin. Exp. Immunol.</i> 75:359-364 (1989).
		VENABLES, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome," <i>J. Autoimmunity</i> 2:439-448 (1989).
		VIRJI & HECKELS, "Location of a Blocking Epitope on Outer-membrane Protein III of <i>Neisseria Gonorrhoeae</i> by Synthetic Peptide Analysis," <i>J. Gen. Microbiol.</i> 135:1895-1899 (1989).
		VOLLER & BIDWELL, "Enzyme-Linked Immunosorbent Assay," Manual of Clinical Laboratory Immunology (Chapter 17) (1986).
		WAGSTAFF, et al., "Aciclovir - A Reappraisal of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy," <i>Drugs</i> 47:153-205 (1994).
		WAITE, et al., "Anti-Jo-1 antibodies are Directed at an Evolutionarily-conserved Conformational Site on Human Histidyl-tRNA Synthetase," <i>Mol. Cell Biol. Autoantibodies Autoimm.</i> 100-101 (1989).
		WALTUCK & BUYON, "Autoantibody-associated Congenital Heart Block: Outcome in Mothers and Children," <i>Ann. Intern. Med.</i> 120:544-551 (1994).
		WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," <i>Med. Hypotheses</i> 25:93-97 (1988).
		WATSON, et al., "Certain Properties Make Substances Antigenic," in <i>Molecular Biology of the Gene</i> , Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	Divisional of 10/012,756
(use as many sheets as necessary)		Filing Date	June 27, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet	23	of	23
		Attorney Docket Number	OMRF 161 DIV (2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		WHITTINGHAM, et al., "Epstein-Barr Virus as an Etiological Agent in Primary Sjogren's Syndrome," <i>Med. Hypothesis</i> , 22:373-386 (1987).
		WILLIAMS, et al., "A Repeated Proline-rich Sequence in Sm B/B' and N is a Dominant Epitope Recognized by Human and Murine Autoantibodies," <i>J. Autoimmunity</i> 3:715-725 (1990).
		WILSON, et al., "Association of Lymphomatoid Granulomatosis With Epstein-Barr Viral Infection of B Lymphocytes and Response to Interferon- $\alpha$ 2b," <i>Blood</i> , 87:4531-4537 (1996).
		WINFIELD, et al., "Serologic Studies in patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction," <i>Arthritis Rheum.</i> 21:289-294 (1978).
		WITEBSKY, et al., "Chronic Thyroiditis and Autoimmunization," <i>J. Am. Med. Assoc.</i> 164:1439-1447 (1957).
		XIE & SNYDER, "Two Short Autoepitopes on the Nuclear Dot Antigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus," <i>Proc. Natl. Acad. Sci.</i> 92:1639-1643 (1995).
		YAMAMOTO, et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," <i>J. Immun.</i> 140:311-317 (1988).
		YOKOCHI, et al., "High Titer of Antibody to the Epstein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 16:1029-1032 (1989).
		YU, et al. "Molecular Mimicry in HLA-B-27-Related Arthritis," <i>Annals of Internal Medicine</i> 111(7):581-591 (1989).
		ZELLER, et al., "Nucleocytoplasmic Distribution of snRNPs and Stockpiled snRNA-Binding Proteins During Oogenesis and Early Development in <i>Xenopus laevis</i> ," <i>Cell</i> 32:425-434 (1983).

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+